Conquering Acute Respiratory Distress Syndrome ARDS and Cancer - Faron Pharmaceuticals

Endothelial barrier is everything

We all face life threatening conditions, if we lose the key property of vasculature - the endothelial barrier. Faron has identified several molecular mechanisms involved in the control of endothelial functions, providing opportunities to develop new unique drugs for true unmet medical need.

Read on ›
Drug development to save lives

Faron's lead drug platform Traumakine prevents vascular leakage through the injured endothelium of several central organs, potentially saving lives of seriously ill patients, e.g. those having acute respiratory distress syndrome (ARDS). The Clevegen project aims at recovering tumour immunity to help the host fight tumour growth and spread by controlling one of the key regulatory pathways connected to several cancers.

Read on ›
World-class expert network

Faron sources innovations from Academia and has built a strong expert network to execute drug development programs. The key opinion leaders play a crucial role in every step of our work, from inventions to clinical protocols and dissemination of results.

Read on ›
Many value inflection points in near future

Faron wants to create shareholder value, not only by advancing the pipeline but also by optimizing commercial steps of Faron products in various territories. Faron has already limited territorial licenses but retains all rights in Europe and USA for all proprietary drug candidates under development.

Read on ›

Lean Drug Development Company

Faron is a drug discovery and development company focussed on creating novel treatments for medical conditions with significant unmet needs. The company is based in Turku, Finland. Faron currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage.


TRAUMAKINE Phase III study targeting the treatment of ARDS

Faron has entered into pan-European pivotal Phase III study with its lead candidate Traumakine®, which targets the treatment of Acute Respiratory Distress Syndrome (ARDS). This study, called INTEREST, aims to achieve conditional European approval and has received €6 million European Union Framework Programme funding (FP7). Currently there is no available drug treatment for ARDS, an orphan lung disease which has a high 30–45% mortality rate.


Faron raising approximately £8.0 million through a Placing and Subscription



Recent news

TURKU – FINLAND, 21 September 2016 – Faron Pharmaceuticals Oy (“Faron” or "Company") (LON: FARN), the clinical stage biopharmaceutical company, is pleased to announce that following the announcement on 20 September 2016, the proposed Placing and Subscription has now conditionally completed.
TURKU – FINLAND, 20 September 2016 – Faron Pharmaceuticals Oy (“Faron” or "Company") (LON: FARN), the clinical stage biopharmaceutical company, is pleased to announce a proposed placing of up to 2,868,000 new ordinary shares in the capital of the Company (the "Placing Shares") and a proposed subscription of up to 332,000 new ordinary shares in the capital of the Company (the “Subscription Shares”) at a price of 250 pence per share (the "Issue Price") to raise, in aggregate, up to approximately £8.0 million before expenses.
Progress continued in Traumakine® Phase III and with Clevegen® indications extended


Traumakine video

Find out the Traumakine® mechanism of action, presented by Professor Geoff Bellingan, medical director at University College London Hospitals (UCLH), who led the Phase II trial.